FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2003 DUSA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) NEW JERSEY 0-19777 22-3103129 (State or other (IRS Employer jurisdiction of (Commission Identification incorporation) File Number) Number) 25 UPTON DRIVE WILMINGTON, MASSACHUSETTS 01887 (Address of principal executive offices, including ZIP code) (978) 657-7500 (Registrant's telephone number, including area code) ITEM 5. OTHER EVENTS. DUSA Pharmaceuticals, Inc. ( "DUSA") issued a press release on September 10, 2003, attached to and made part of this report, noting receipt of 510(k) marketing clearance from the United States Food and Drug Administration for the BLU-U(R) Blue Light Photodynamic Therapy Illuminator Model 4170 to treat dermatological indications and specifically, moderate inflammatory acne vulgaris. ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS. (c) Exhibits. [99] Press Release dated September 10, 2003. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DUSA PHARMACEUTICALS, INC. Dated: September 11, 2003 By: /s/ D. Geoffrey Shulman -------------------------------------- D. Geoffrey Shulman, MD, FRCPC President, Chief Executive Officer